Kongresse und Veröffentlichungen

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL) BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) CaDAnCe-104, an ongoing, open-label, phase 1b/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma Changes in real-world treatment patterns over time by patient characteristics and time burden of treatment in CLL/SLL Chemo ± immunotherapy remains utilized for chronic lymphocytic lymphoma in the real-world practice: Unmet needs, treatment patterns and age disparities in the United States Evaluation of factors from established prognostic models in patients with chronic lymphocytic leukemia (CLL) treated with zanubrutinib: A post-hoc analysis of two phase 3 studies (SEQUOIA and ALPINE) Final analysis of the randomized phase 2 ROSEWOOD study of zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia Indirect comparison of efficacy of zanubrutinib vs ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma Long-term results of patients receiving zanubrutinib in the phase 3 ALPINE study confirm sustained benefit of zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL): Up to 6 years of follow-up with the long-term extension (LTE1) MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: Initial results from an ongoing phase 1/1b study, BGB-11417-101 Mediators of racial and ethnic inequities in access to front-line therapies for chronic lymphocytic leukemia in the United States: A real-world evidence study Number needed to treat to avoid progression or death: Zanubrutinib vs other covalent Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia Outcomes during BTKi treatment for chronic lymphocytic leukemia: Insights from remote therapeutic monitoring Patient preferences and factors affecting patient treatment decisions for chronic lymphocytic leukemia (CLL) in Japan Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) Progression-free survival in patients with low health-related quality of life treated with zanubrutinib versus ibrutinib monotherapy: Post hoc analysis of the ALPINE trial Real-world treatment patterns and biomarker utilization among patients aged ≥65 years with CLL/SLL from 2020 to 2024 Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia Sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) previously treated with a Bruton tyrosine kinase (BTK) inhibitor: Early results from a phase 1/2 study Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) and continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Results from the ALPINE trial Treatment patterns and outcomes among patients treated with second-generation BTK inhibitors in CLL Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study Zanubrutinib + obinutuzumab + sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL): Initial results from an ongoing phase 1/1b study, BGB-11417-101 Zanubrutinib + venetoclax for treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including patients with del(17p) and/or TP53 mutation and unmutated immunoglobulin heavy-chain variable status: 3 year results from SEQUOIA Arm D Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies: A long-term follow-up

First-line (1L) tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Japanese subgroup analysis

First-line (1L) tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Japanese subgroup analysis

SEQUOIA 5-year follow-up (arm C): zanubrutinib in patients with del(17p) and treatment-naïve CLL/SLL

SEQUOIA 5-year follow-up (arm C): zanubrutinib in patients with del(17p) and treatment-naïve CLL/SLL Zanubrutinib vs venetoclax+obinutuzumab in treatment-naive (TN) chronic lymphocytic leukemia (CLL)

A first-in-human, phase 1 study of BGB-15025 (hematopoietic progenitor kinase 1 inhibitor) as monotherapy and in combination with tislelizumab (anti-PD-1 antibody) in patients with advanced solid tumors First-in-human, phase 1 study of BGB-26808 (hematopoietic progenitor kinase 1 inhibitor) ± tislelizumab (anti-PD-1) in advanced solid tumors First-line tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): A post-hoc analysis of different investigator-choice CT and tumor PD-L1 expression level subgroups in RATIONALE-306 First-line tislelizumab + chemotherapy (CT) vs placebo + CT in extensive-stage small cell lung cancer: long-term follow-up of RATIONALE-312 Tislelizumab plus chemotherapy for first-line advanced or metastatic squamous non-small cell lung cancer: Long-term overall survival subgroup analysis of RATIONALE-307 Tislelizumab treatment beyond progression in advanced sq-NSCLC after 1l chemoimmunotherapy: Results from randomized, phase III RATIONALE-307 study Tislelizumab with or without capecitabine continuation in gastric or gastro-oesophageal junction cancer: RATIONALE-305 post hoc analysis

A first-in-human, phase 1 study of BGB-15025 (hematopoietic progenitor kinase 1 inhibitor) as monotherapy and in combination with tislelizumab (anti-PD-1 antibody) in patients with advanced solid tumors First-in-human, phase 1 study of BGB-26808 (hematopoietic progenitor kinase 1 inhibitor) ± tislelizumab (anti-PD-1) in advanced solid tumors First-line tislelizumab + chemotherapy (CT) vs placebo + CT in extensive-stage small cell lung cancer: long-term follow-up of RATIONALE-312 Tislelizumab plus chemotherapy for first-line advanced or metastatic squamous non-small cell lung cancer: Long-term overall survival subgroup analysis of RATIONALE-307 Tislelizumab treatment beyond progression in advanced sq-NSCLC after 1l chemoimmunotherapy: Results from randomized, phase III RATIONALE-307 study Tislelizumab with or without capecitabine continuation in gastric or gastro-oesophageal junction cancer: RATIONALE-305 post hoc analysis

Direct medical costs of nasopharyngeal carcinoma in Indonesia: a healthcare payer perspective

Direct medical costs of nasopharyngeal carcinoma in Indonesia: a healthcare payer perspective

Updated interim results of sonrotoclax + dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma (R/R MM): an all-oral treatment

Updated interim results of sonrotoclax + dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma (R/R MM): an all-oral treatment